PharmaCom BioVet, Inc.

March 11, 2009 07:31 ET

PharmaCom BioVet, Inc. Expands On Strategic Alliances

RALEIGH, NORTH CAROLINA--(Marketwire - March 11, 2009) - PharmaCom BioVet, Inc. (PINKSHEETS:PHMB) is pleased to announce that discussions are ongoing with companies specializing in our field area of focus. It is anticipated that strategic partnerships of this nature will greatly enhance the potential of the business model designed and now being implemented by management.

"We are realising the importance and significance of the strategic partnering with companies with which we have a high degree of synergy", stated Mr. Gary Berthold, President of PharmaCom BioVet, Inc.

In order to advance the business model of creating a nationwide network of Veterinary Oncology Treatment Centers, the company will research and engage in these partnering opportunities in the near future.

About Us:

PharmaCom BioVet, Inc. is quickly positioning itself to becoming the leader in specialized veterinary oncology (cancer treatment facilities for animals). PHMB management is planning the rollout of specialized Veterinary Oncology Treatment Centers that will be strategically located throughout the United States. PHMB has licensed a series of proprietary devices and compounds that will enable animals suffering from cancer a potentially greater life expectancy and decreased suffering.

On behalf of the Board of Directors,

Mr. Gary Berthold


"Safe Harbour" statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that are subject to risk and uncertainties, including, but not limited to, the impact of competitive products, product demand, market acceptance risks, fluctuations in operating results, political risk and other risks detailed from time to time in PharmaCom BioVet, Inc.'s filings with the Securities and Exchange Commission. These risks could cause PharmaCom BioVet, Inc.'s actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, PharmaCom BioVet, Inc.

Contact Information